Monitoring Adverse Drug Reactions to Tuberculosis Drugs among Category 1 Patients at Bojonegoro Health Center
DOI:
10.29303/jbt.v26i2.12276Published:
2026-06-11Downloads
Abstract
Tuberculosis caused by Mycobacterium tuberculosis remains a major public health issue in Indonesia. Prolonged use of anti-tuberculosis medications may lead to adverse drug reactions (ADRs). This study aimed to describe the incidence and characteristics of ADRs among Category 1 tuberculosis patients at Bojonegoro Health Center. A descriptive observational study with a retrospective design was conducted during April–May 2026 using medical records and structured interviews. The study sample consisted of 37 patients selected from a population of 40 using the Slovin formula and purposive sampling technique. Data were analyzed descriptively using frequency and percentage distributions, while ADR causality was evaluated using the Naranjo algorithm. The results indicated that ADRs were more frequently observed in female patients, individuals aged 46–55 years, and during the intensive phase of treatment. The most commonly reported ADR was reddish urine discoloration (100.0%), followed by anorexia (67.6%) and nausea (59.5%). Most ADRs were classified as mild to moderate in severity, while decreased vision was reported in 10.8% of patients. Based on the Naranjo scale, 93.4% of ADRs were categorized as probable. Regular monitoring of ADRs is recommended to support early detection and appropriate management during anti-tuberculosis therapy.
Keywords:
Anti-Tuberculosis Drugs Adverse Drug Reaction ADR Monitoring Category 1 Tuberculosis Patients TuberculosisReferences
Abebe, G., & , Zegeye Bonsa, W. K. (2024). Treatment Outcomes and Associated Factors in Tuberculosis Patients at Jimma University Medical Center: A 5‑Year Retrospective Study Gemeda. International Journal of Mycobacteriology, 6(3), 239–245. https://doi.org/10.4103/ijmy.ijmy
Agustina, R., Maulida, R., & Yovsyah. (2023). Factors Associated with Recovery Success after Short Treatment Regiment among Drug Resistant Tuberculosis Patients in Indonesia 2017. Jurnal Epidemiologi Kesehatan Indonesia, 2(2), 65–71. https://doi.org/10.7454/epidkes.v2i2.3048
Ahdiyah, N. N., Andriani, M., & Andriani, L. (2022). Tingkat Kepatuhan Penggunaan Obat Anti Tuberkulosis Pada Pasien TB Paru Dewasa Di Puskesmas Putri Ayu. Lumbung Farmasi: Jurnal Ilmu Kefarmasian, 3(1), 23. https://doi.org/10.31764/lf.v3i1.6817
Albert , Clinique, L. D. P., Pharmacie, F. De, Lebrun, A., & Bp, L. (2024). Hiding in Plain Sight: Revisiting a Case of Antitubercular Drug Induced Chromaturia. 2(33),0–1.https://doi.org/10.47616/ jamr mhss .v5i2.541
Bariyah, F., & Karuniawati, H. (2025). ORIGINAL ARTICLE Evaluation of Adverse Drug Reaction in Pediatric Tuberculosis Patients at The Tegal District Public Health Center Evaluasi Adverse Drug Reaction pada Pasien Tuberkulosis Anak di Puskesmas Kabupaten Tegal Pendahuluan Metode Penelitian Peri. 2721–2729. https://doi.org/10.36490/ journal-jps.com.v8i4.1157
Dianita, S., Siswidiasari, A., & P, T. S. A. (2026). Sains Medisina. 4(3), 304–309. https://doi.org/10.63004/snsmed.v4i3.957
Djochie, R. D. A., Anto, B. P., & Opare-Addo, M. N. A. (2023). Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. Journal of Pharmaceutical Policy and Practice, 16(1), 1–10. https://doi.org/10.1186/s40545-023-00577-6
Farhanisa, U. (2021). Kejadian Efek Samping Obat Anti Tuberkulosis (Oat) Kategori 1 Pada Pasien Tb Paru Di Unit Pengobatan Penyakit Paru-Paru (Up4) Provinsi Kalimantan Barat. In Jurnal Surya Medika (Vol. 2, Issue 2, pp. 2234–2239).
Farina1, Reny Haryani1,2, M. B. (2025). IDENTIFIKASI ADVERSE DRUG REACTIONS PENGGUNAAN OBAT ANTI TUBERKULOSIS PARU PADA PASIEN DI SALAH SATU PUSKESMAS KOTA BATAM. Jurnal Kesehatan Madani Medika, Vol 16, (Hal : 44-52 ). https://doi.org/10.36569/jmm.v16i1.462
Haryani, R., & Badar, M. (2025). Identification of Adverse Drug Reactions in the Use of Anti-Tuberculosis Drugs in Patients at a Public Health Center in Batam. Jurnal Kesehatan Madani Medika, 16(01), 44–52. https://doi.org/10.36569/jmm.v16i1.462
Jorge, M. J., Esporlas, C. B., Largoza, M. L. E., & Zamora, R. (2024). Adverse Drug Events from First-Line Anti-tuberculosis Drugs in a Tertiary Medical Center. European Medical Journal, December 2024, 113–119. https://doi.org/10.33590/emj/qyjr8314
Kemenkes RI 2016. (n.d.). Efek Samping Obat Antituberkulosis (OAT) Lini Pertama pada Penderita TB Paru di Puskesmas X Kota Bekasi Periode Januari – Maret 2025. https://doi.org/10.37277/sfj.v18i2.2354
Khan, Mandal, R. K., Elasbali, A. M., Dar, S. A., Jawed, A., Wahid, M., Mahto, H., Lohani, M., Mishra, B. N., Akhter, N., Rabaan, A. A., & Haque, S. (2019). Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: Trial sequence meta-analysis as evidence. Bioscience Reports, 39(1), 1–15. https://doi.org/10.1042/BSR20180845
Kumar, N., Kanchan, T., Unnikrishnan, B., Thapar, R., Mithra, P., Kulkarni, V., Holla, R., Bhagwan, D., & Radhakrishnan, Y. (2024). Characterization of Rubia cordifolia L. root extract and its evaluation of cardioprotective effect in Wistar rat model. Indian Journal of Pharmacology, 49(5), 344–347. https://doi.org/10.4103/ijp.IJP
Lucia Vita I.D., M. S. (2023). suhan kefarmasian klinik adverse drug reaction (ADR) “pharmacovigilance” Dosen Pengampu Dr . apt . Lucia Vita I . D ., M . Sc . PROGRAM STUDI PROFESI APOTEKER XLVI. https://doi.org/10.1111/bcp.15908
Novalisa, N., Susanti, R., & Nurmainah, N. (2022). Analisis Faktor-faktor yang Mempengaruhi Kepatuhan Penggunaan Obat Tuberkulosis pada Pasien di Puskesmas. Journal Syifa Sciences and Clinical Research, 4(1), 342–353. https://doi.org/10.37311/jsscr.v4i2.14195
Nur Madania, M., Sutriati Tuloli, T., Abdulkadir, W. S., Ahmad, H., & Angraini Suwandi, T. B. (2023). Studi Efek Samping Obat Antituberkulosis (OAT) Pada Pasien TB Paru. Journal Syifa Sciences and Clinical Research, 4(3), 707–717. https://doi.org/10.37311/jsscr.v4i3.16657
Permana, D. A. S. (2022). Identifikasi Adverse Drug Reaction Penggunaan Obat Anti Tuberkulosis Paru Di Uptd Puskesmas Kroya I Periode Januari 2019. Jurnal MIPA Sains Terapan, 1(1), 1–8. https://journal.unindra.ac.id/index.php/sainsmath/article/view/1234
Puspitasari, I. M., Insani, W NIfayani, O., & Pradipta, I. S. (2023). Efek Samping Obat Pada Pengobatan Tuberkulosis Resisten Obat Ganda. In Majalah Farmasi dan Farmakologi (Vol. 27, Issue 1, pp. 10–11). https://doi.org/10.20956/mff.v27i01.25660
Rokiban, A., & Maykasari, K. (2024). Evaluasi Penggunaan Obat Anti Tuberkulosis (OAT) pada Pasien TB Paru di Puskesmas Punggur Kabupaten Lampung. Jurnal Farmasi IKIFA, 3(1), 59–70.
Sontakke, R, P., & S, A. (2024). Adverse Drug Reactions in Intensive / Initial Phase of Antitubercular Treatment in Patients of Tuberculosis. International Journal of Science and Research (IJSR), 13(10), 1745–1751. https://doi.org/10.21275/sr241021223722
Sugiyono. (2021). Metode Penelitian Kuantitatif, Kualitatif Dan R & D - Prof. Dr. Sugiyono 2017. Alfabeta.
Syahrina, N. A., W, S. P. T., Karsidin, B., Madhiyyah, C. A., & Sumari, S. (2024). Analysis of Adherences and Effectiveness in Tuberculosis Patients at a Hospital in West Java Province in Indonesia. Saudi Journal of Medical and Pharmaceutical Sciences, 10(12), 888–894. https://doi.org/10.36348/sjmps.2024.v10i12.002
World Health Organization. (2024). Gambaran efek samping penggunaan obat antituberkulosis pada penderita tuberkulosis paru di RSUD Dr. M. Yunus Bengkulu periode 2021. https://doi.org/10.37676/jnph.v12i1.6368
Wormald, R., Humphreys, P. N., Charles, C. J., & Rout, S. P. (2023). Bacillus-based probiotic cleansers reduce the formation of dry biofilms on common hospital surfaces. MicrobiologyOpen, 12(6), 1–8. https://doi.org/10.1002/mbo3.1391
Yudiana, R., Zulmansyah, & Garna, H. (2022). Hubungan Kepatuhan Terapi Obat Anti-Tuberkulosis ( OAT ) Kombinasi Dosis Tetap ( KDT ) dengan Kesembuhan Pasien Tuberkulosis Paru Dewasa di Puskesmas Patokbeusi Subang The Relationship between Medication Adherence with Anti-Tuberculosis Drug Therapy (OAT). Jurnal Integrasi Kesehatan Dan Sains (JIKS) Online, 4(1), 52–55. https://doi.org/10.29313/jiks.v4i1.9334.
License
Copyright (c) 2026 Nadhi Fatul Kholillah, Titi Agni Hutahaen, Ria Indah Kusuma Pitaloka
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
